Dual targeting

Patent metadata

Field	Value
Publication number	US-9944719-B2
Application number	US-201314650083-A
Country	US
Kind code	B2
Filing date	Dec 5, 2013
Priority date	Dec 5, 2012
Publication date	Apr 17, 2018
Grant date	Apr 17, 2018

Abstract

The present invention relates to antibody-based dual targeting molecules, and to methods for generating such dual targeting molecules, including a library-based approach.

First claim

The invention claimed is:

1. Rewrite as “A collection of antibodies or functional fragments thereof, wherein said collection comprises a diverse collection of antibody variable domain sequences wherein said antibody variable domain sequences comprise a combination of a VL domain and a VH domain,
(A)
a. wherein said VL domain is based on a framework selected from SEQ-ID NOs: 1, 3, 5, and 7, wherein said VL domain is diversified in accordance with the diversification scheme shown in any one of SEQ-ID NOs: 8, 12, 18 or 19; and
b. wherein said VH domain is based on a framework selected from SEQ-ID NOs: 2, 4 and 6, wherein said VH domain is diversified in accordance with the diversification scheme shown in any one of SEQ-ID NOs: 9, 13, 20 or 21;
c. provided that a combination of a VL domain based on SEQ-ID NO: 1, which is diversified in accordance with the diversification scheme shown in SEQ-ID NOs: 18 or 19, and a VH domain based on SEQ-ID NO: 2, which is diversified in accordance with the diversification scheme shown in SEQ-ID NOs: 20 or 21 is excluded; or
(B)
a. wherein said VL domain is based on a framework selected from SEQ-ID NOs: 1, 3, 5, and 7, wherein said VL domain is diversified in accordance with the diversification scheme shown in any one of SEQ-ID NOs: 10, 14, 16, 22 or 23; and
b. wherein said VH domain is based on a framework selected from SEQ-ID NOs: 2, 4 and 6, wherein said VH domain is diversified in accordance with the diversification scheme shown in any one of SEQ-ID NOs: 11, 15, 17, 24, 25 or 26;
c. provided that a combination of a VL domain based on SEQ-ID NO: 1, which is diversified in accordance with the diversification scheme shown in SEQ-ID NOs: 22 or 23, and a VH domain based on SEQ-ID NO: 2, which is diversified in accordance with the diversification scheme shown in SEQ-ID NOs: 24, 25 or 26 is excluded.”

2. A method for producing the collection of antibodies or functional fragments thereof according to claim 1 , comprising the step of (i) expressing a collection of nucleic acid sequences encoding the collection of antibodies or functional fragments thereof according to claim 1 , (ii) expressing a collection of nucleic acid sequences from a collection of vectors, particularly expression vectors, comprising a collection of nucleid acid sequences encoding the collection of antibodies or functional fragments thereof according to claim 1 , and/or (iii) cultivating a collection of host cells comprising a collection of nucleic acid sequences encoding the collection of antibodies or functional fragments thereof according to claim 1 , under conditions that cause or allow the expression of the nucleic acid sequences.

3. A method for identifying an antibody or functional fragment thereof with binding specificity for a target of interest, comprising the steps of contacting the collection of antibodies or functional fragments thereof according to claim 1 with the target of interest and screening or selecting for antibodies or functional fragments thereof with binding specificity for said target of interest.

4. The method of claim 3 , wherein said screening or selecting is using phage display.

Assignees

• Dutalys Gmbh
• Hoffmann La Roche

Inventors

• Beckmann Roland
• Jensen Kristian

Classifications

• C07K2317/31

  multispecific · CPC title

• C07K16/248

  IL-6 · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K16/22

  against growth factors {; against growth regulators} · CPC title

• C07K16/243

  Colony Stimulating Factors · CPC title